companydata.dkcompanydata.dk

Øresund Pharma ApS: Financial statements 2024

CVR: 39492059

Source: annual report 2024, Danish Business Authority

01/01/2024 – 31/12/2024

Øresund Pharma ApS (CVR 39492059) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 39,622,065 and a net result of DKK 13,707,320 compared with DKK 16,750,969 the year before. That is an increase of 3.6% compared with the year before. Equity in the 2024 report amounted to DKK 38,150,718. The solvency ratio was 47%. The company had 11 employees in the financial year.

Gross Profit
DKK 39,622,065
Profit/Loss
DKK 13,707,320
Equity
DKK 38,150,718
Total Assets
DKK 81,088,602
Employees
11

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024-39.6 mio.13.7 mio.38.2 mio.11
2023-38.3 mio.16.8 mio.24.4 mio.9
2022-17.2 mio.4.3 mio.7.7 mio.6
2021-7.3 mio.281 t.3.4 mio.5
2020-2.8 mio.-86 t.3.1 mio.4

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2024

Øresund Pharma ApS wins public contractNov 11, 2024

Øresund Pharma ApS has won the tender "Amgros 2025 1.400.a" issued by Amgros I/S worth 1,010,000 DKK.

Øresund Pharma ApS wins public contractOct 29, 2024

Øresund Pharma ApS has won the tender "Amgros 2025 1.1302.a" issued by Amgros I/S worth 17,702,414 DKK.

Øresund Pharma ApS wins public contractOct 24, 2024

Øresund Pharma ApS has won the tender "Amgros 2025 1.700.a" issued by Amgros I/S worth 313,301,544 DKK.

Øresund Pharma ApS wins public contractOct 24, 2024

Øresund Pharma ApS has won the tender "Amgros 2025 1.1200.a" issued by Amgros I/S worth 101,036,383 DKK.

Øresund Pharma ApS wins public contractOct 23, 2024

Øresund Pharma ApS has won the tender "Amgros 2025 1.1202.a" issued by Amgros I/S worth 90,124,932 DKK.

Øresund Pharma ApS wins public contractOct 17, 2024

Øresund Pharma ApS has won the tender "Amgros 2025 2.3.b" issued by Amgros I/S worth 359,770,187 DKK.

Øresund Pharma ApS wins public contractOct 17, 2024

Øresund Pharma ApS has won the tender "Amgros 2025 1.703.b" issued by Amgros I/S worth 12,600,000 DKK.

Øresund Pharma ApS wins public contractOct 3, 2024

Øresund Pharma ApS has won the tender "Amgros 2025 1.1142.b" issued by Amgros I/S worth 153,000,000 DKK.

Svend Aage Johansen joins Øresund Pharma ApS as directorApr 1, 2024

As of April 1, 2024, Svend Aage Johansen is registered as director of Øresund Pharma ApS.

Øresund Pharma ApS: The 2023 annual report is outMar 5, 2024

Øresund Pharma ApS has published its annual report for 2023. Gross profit came to DKK 38,259,550, and the net result was DKK 16,750,969.

About Øresund Pharma ApS

Øresund Pharma ApS is a Danish company of the type Anpartsselskab based in Nordhavn, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Øresund Pharma IVS. The management consists of Patrick Halborg Cohn and Svend Aage Johansen. The company is owned by Machpali ApS and ESH Holding 2019 ApS. The company has 21 employees (2026). In 2025, the company reported a gross profit of DKK 39,702,011 and a net result of DKK 6,466,876 compared with DKK 13,707,320 the year before. Equity in the 2025 report amounted to DKK 44,617,595.

Source: annual report 2025, Danish Business Authority

Other financial years